IL27 and neoplasm: The overall impact of IL-27 gene therapy on the tumor microenvironment was assessed by initially implanting subcutaneous TC2Ras tumors in mice followed by the intramuscular delivery of plasmid expressing IL-27pepL or a control plasmid, aided by sonoporation.